Richard joined the company in 2017, when the company was known as BresMed. He has over 5 years of experience in health outcomes statistics, systematic reviews, meta-analysis, evidence-based medicine, and survival analyses. Before moving into the field of health technology assessment (HTA), Richard worked as a research scientist; he has a PhD in molecular biology and has studied a wide range of different cancers including prostate, colorectal, and medulloblastoma. Richard brings a strong understanding of fundamental biological principles in oncology and experience across a range of disease areas including ophthalmology and multiple sclerosis. He has been responsible for statistical input to HTA submissions, including survival and utility analysis. He has also worked as part of an Evidence Review Group on behalf of NICE, reviewing UK HTA submissions.